Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kevzara is an IL-6 only inhibitor. Contraindicative side effects in COVID-19 and suppresses the immune system. Inferior to leronlimab.
Minimum financials for Nasdaq listing we haven't met yet.
Stockholders’ Equity -$4 million
Net Tangible Assets - $2 million and a 3 year operating history
Working Capital - sufficient for 12 months or a credible revenue plan that would cover 12 months working capital
All achievable with COVID-19 or HIV approval.
No. 6 is amusing "Market Cap: 19.81M"
I think they went on a shoe video shoot in the midst of CoVID-19. Hopefully they haven't succumbed or we'll never know whether L4L shoes are in stock.
As a merged company the activity of L4L would have to be reflected in the RBNW filings as of the date of merger. If it isn't then the RBNW filing would be fraudulent.
It just did - .0012 to .0015. Now sell $200 worth of shares and crash the price back down.
With J and J only having 17 billion cash on hand it's unlikely.
Where's the inventory for L4L? Where is the income?
All you investors have been had.
Your the last person to talk about educated statements.
You're right GILD should take a hit.
On your mythical trading day 200% from current share price with 20m volume would be $60,000 profit. That would assume that you bought all 20 million shares and it would stay at .003 instead of dropping like a lead weight on the sell off. If you made $600 I would be surprised. Now the only probably is that 200% up is nowhere to be seen.
If Gilead was smart they would have made a reasonable offer in 2018. An acceptable offer now would burn through a very large portion of their cash reserves. I don't see offers from any BP coming in before COVID-19 approval and afterwards they won't be able to afford us.
GILD would face shareholder lawsuits and have the Board of Directors and CEO thrown out if they made an appropriate offer.
A quick glance shows that Arcus has anti-PD-1 drugs. Gilead could go head to head with Keytruda. Meanwhile lowering PD-1 is just one of the ways leronlimab fights cancer.
This time around they might offer one cent above share price.
Gilead talked to Cytodyn several years ago and they lowballed us. Since then it seems Gilead thinks they can buy elsewhere to outcompete leronlimab.
What has ATOS done? Announce that they're going to combine two unspecified drugs and bring them to trial. If the shorts want a target ATOS is a much better one.
Are you part of the HB crew?
Another drug that does part of what leronlimab does.
My transcription skills aren't bad either.
We know Dr. Lalezari was supposed to talk to Dr. Fauci. I'm sure it wasn't for old times sake.
They've licensed out a technology that may one day produce an antiviral compound. Your posts are pure comedy.